Oncolytics Biotech IncONCY
Price$0.64

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$37.5MTTM through 30 Jun 2026
Free Cash Flow -$26.7MTTM through 30 Jun 2026

Margins

Current

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.88x
Net Debt-$5.5Mnet cash position
Cash & Equivalents$4.1M

Quality Metrics

Altman Z-Score-93.79
Piotroski F-Score1 / 9
Earnings-Beat Rate33.3%

Multi-Year Trend

Diluted EPS-$0.35TTM
'24'25
FY2025: $-0.30

Dividend

No dividend

Capital Allocation

R&D Spend$17.4M

Segment Performance

SegmentRevenueYoYOutlook
Immunotherapy Drug Development$0
View details

Sharpened focus on advancing pelareorep into registration-enabling studies while managing severe liquidity constraints.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.